FDA Authorizes Emergency Use of Dectomax CA-1 for Dairy Cattle
The U.S. Food and Drug Administration has issued an Emergency Use Authorization for Dectomax CA-1, a drug aimed at preventing and treating New World Screwworm infestations in dairy cattle. Sponsored by Zoetis, the drug is now authorized for use in various types of dairy cattle, including lactating and dry cows as well as replacement heifers aged 20 months and older. However, it is not approved for use in dairy calves intended for veal production.
Additional Livestock Authorizations
The authorization extends beyond dairy cattle, allowing the use of Dectomax CA-1 in swine, horses at least one year old, sheep (excluding those that are lactating), and deer. The FDA has determined, based on scientific evidence, that it is reasonable to believe the drug may be effective in treating New World Screwworm infestations.
Regulatory Limitations
Several limitations accompany this authorization. Treated livestock must adhere to a milk discard time of 468 hours post-treatment. Additionally, there are slaughter withdrawal periods of 35 days for dairy cows, sheep, and deer, and 24 days for swine. The USDA specifically prohibits the use of Dectomax CA-1 in pre-ruminating calves, horses under the age of one year, and lactating sheep.
This Emergency Use Authorization will remain in effect until it is revoked by the FDA, underscoring its temporary nature. It is part of a broader effort to manage and control the spread of New World Screwworm, a pest that poses significant risks to livestock health and agricultural productivity.
